Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 757

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

Stromal biology and therapy in pancreatic cancer

Neesse, Albrecht, Michl, Patrick, Frese, Kristopher K, Feig, Christine, Cook, Natalie, Jacobetz, Mike A, Lolkema, Martijn P, Buchholz, Malte, Olive, Kenneth P, Gress, Thomas M, Tuveson, David A·2011·Gut

Abstract

Pancreatic ductal adenocarcinoma (PDA) is an almost uniformly lethal disease. One explanation for the devastating prognosis is the failure of many chemotherapies, including the current standard of care therapy gemcitabine. Although our knowledge of the molecular events underlying multistep carcinogenesis in PDA has steadily increased, translation into more effective therapeutic approaches has been inefficient over the last several decades. Evidence for this innate resistance to systemic therapies was recently provided in an accurate mouse model of PDA by the demonstration that chemotherapies are poorly delivered to PDA tissues because of a deficient vasculature. This vascular deficiency correlated with the presence of a dense stromal matrix that is a prominent histological hallmark of PDA tumours. Therapeutic targeting of stromal cells decreased the stroma from pancreatic tumours, resulting in increased intratumoral perfusion and therapeutic delivery of gemcitabine. Stromal cells contained within the PDA tumour microenvironment therefore represent an additional constituent to neoplastic cells that should be critically evaluated for optimal therapeutic development in preclinical models and early clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gut.2010.226092

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 87 references

Research works printed but not linked: 10

  1. Rothenberg, 1996, A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer, Ann Oncol, 7, 347, 10.1093/oxfordjournals.annonc.a010600 · doi:10.1093/oxfordjournals.annonc.a010600
  2. Crist, 1987, Improved hospital morbidity, mortality, and survival after the Whipple procedure, Ann Surg, 206, 358, 10.1097/00000658-198709000-00014 · doi:10.1097/00000658-198709000-00014
  3. Trede, 1990, Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality, Ann Surg, 211, 447, 10.1097/00000658-199004000-00011 · doi:10.1097/00000658-199004000-00011
  4. 10.1007/s11938-005-0039-3 · doi:10.1007/s11938-005-0039-3
  5. 10.1111/j.1749-6632.1999.tb09533.x · doi:10.1111/j.1749-6632.1999.tb09533.x
  6. 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.0.CO;2-O · doi:10.1002/(sici)1097-0215(20000101)85:1<14::aid-ijc3>3.0.co;2-o
  7. Buchholz, 2003, SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo, Cancer Res, 63, 4945
  8. 10.1016/j.bbrc.2004.08.229 · doi:10.1016/j.bbrc.2004.08.229
  9. 10.1159/000107400 · doi:10.1159/000107400
  10. 10.1002/cncr.10323 · DOI · Paper page

Cited by

See all 757

Metadata

Authors
Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., & Tuveson, D. A.
Venue
Gut
Publisher
BMJ
Published
2010-10-21
Volume
60
Issue
6
Pages
861-868
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2131070390
Cited by
757
References
87
FWCI
14.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stromal biology and therapy in pancreatic cancer. https://app.cochat.ai/papers/10.1136/gut.2010.226092
The paper
Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., & Tuveson, D. A. (2011). Stromal biology and therapy in pancreatic cancer. Gut. https://doi.org/10.1136/gut.2010.226092

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.